VTRS
NASDAQ · Pharmaceuticals
Viatris Inc
$18.97
-0.25 (-1.30%)
Financial Highlights (FY 2026)
Revenue
14.00B
Net Income
-3,441,850,412
Gross Margin
39.5%
Profit Margin
-24.6%
Rev Growth
-4.2%
D/E Ratio
0.98
Revenue & Net Income
Margin Trends
| FY 2026 | FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|---|
| Gross Margin | 39.5% | 39.5% | 35.8% | 35.8% |
| Operating Margin | -19.3% | -17.4% | 29.8% | 37.8% |
| Profit Margin | -24.6% | -23.4% | 27.9% | 27.3% |
Income Statement
| FY 2026 | FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|---|
| Revenue | 14.00B | 14.62B | 3.47B | 3.37B |
| Gross Profit | 5.54B | 5.78B | 1.24B | 1.20B |
| Operating Income | -2,708,109,808 | -2,544,153,264 | 1.03B | 1.27B |
| Net Income | -3,441,850,412 | -3,233,471,159 | 966.90M | 917.66M |
| Gross Margin | 39.5% | 39.5% | 35.8% | 35.8% |
| Operating Margin | -19.3% | -17.4% | 29.8% | 37.8% |
| Profit Margin | -24.6% | -23.4% | 27.9% | 27.3% |
| Rev Growth | -4.2% | -4.2% | -2.8% | +22.9% |
Balance Sheet
| FY 2026 | FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|---|
| Total Debt | 5.40B | 5.40B | 4.37B | 3.63B |
| Total Equity | 5.51B | 5.51B | 12.59B | 11.78B |
| D/E Ratio | 0.98 | 0.98 | 0.35 | 0.31 |
Cash Flow
| FY 2026 | FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|---|
| EBITDA | 31.75M | 31.49M | 1.51B | 1.62B |
| Free Cash Flow | — | — | 925.81M | 1.00B |